# OnCo record nct04333706 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04333706/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04333706", "NCT04333706" ;
  schema:name "A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S"@en ;
  schema:alternateName "EMPOWER"@en ;
  schema:description "A phase 1/2 trial of capecitabine in triple-negative breast cancer, run by University of Southern California, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04333706/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04333706> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> .